XNCR · Xencor Inc

Track XNCR — free

$24.41 +0.15 (+0.62%) At close · Sep 11

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$1.81B

74.35M

Up next

Next earnings call

Dec 29, 2026 Est · unconfirmed · in 15 wks

Latest filing: 10-Q

filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$104.97M

Trailing 12 months

Net income (TTM)

−$163.11M

Trailing 12 months

Revenue growth YoY

+17.5%

Year over year

Operating margin

-205.8%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-11.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.1%

Year over year · more shares

Price change (1Y)

+187.2%

Trailing year

Short interest

20.1%

Latest settlement · 9.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +59%

above

Price vs 50-day avg +12%

above

RSI (14) 48

neutral

MACD trend Negative

52-week position 77%

mid-range

Momentum

relative strength

Very Strong

1-month return +6%

trailing

6-month return +101%

trailing

YTD return +59%

this year

Relative strength +83%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $22 › 200d $15 — 50d above 200d

Institutional flow Accumulating

+2% holders QoQ · +32 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

20.06% of float · ▲ +5.1% MoM · 9.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

208 holders — near 3-yr high, broad support

Squeeze score 75

high risk · 0–100

Fundamentals

Fair

Revenue growth +14%

Y/Y

EPS growth +65%

Y/Y

Free cash flow $-138.3M

Balance sheet $65.7M

net debt

Quant / Vol

risk profile

Very High

Volatility 67%

annualized · 1-yr

Max drawdown −43%

past year

ATR 6.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 5, 2026

Cash, cash equivalents and marketable debt securities · year end 2026 $420M – $440M

Prior guidance period ended · from the 8-K filed Aug 5, 2024

Cash, cash equivalents and marketable debt securities · end of 2024 $475M – $525M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+59% Bullish

Price vs 50-day avg

+12% Bullish

RSI (14)

48 Neutral

MACD trend

Negative Bearish

52-week position

77% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $22 › 200d $15 — 50d above 200d

Institutional flow Accumulating

+2% holders QoQ · +32 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

20.06% of float · ▲ +5.1% MoM · 9.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

208 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $8 Now $24 · 77% Range high $29

vs 200-day avg +59% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
XNCR Xencor Inc this stock	$1.81B	+59.4%	+13.7%	—	20.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.64B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$80.46B	+1.2%	+20.8%	19.4	2.5%
ARGX Argenx SE	$61.22B	+17.1%	—	—	2.0%
MRNA Moderna, Inc.	$57.48B	+388.2%	+4.3%	—	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

208

% held: 113.2%
Net QoQ: -290.2K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

249

View

Short & Settlement

Short Interest Rising

Shares short

14.9M

Days to cover: 9.5d
Change: +724.3K sh

View

Short Volume

Short vol %

63%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

6.5K

Value: $142.6K
As of: Aug 12, 2026

View

Off-Exchange

Off-exchange %

45.7%

Week of: Aug 3, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$125.6M

Net income (FY): $-91.9M
EPS diluted: $-1.24

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 14

View

Proposed Sales

Value

$89.4K

Shares: 6.8K
Filed: Jun 18, 2026

View

Exempt Offerings

Offering

$25.0M

Filed: Nov 19, 2021

View

Earnings & Events

Earnings Calls

Last call

May 5, 2026

View

Performance

	5D	20D	120D	MTD	YTD
XNCR	-8.3%	+6.2%	+101.2%	-10.5%	+59.4%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-7.2%	+7.9%	+83.4%	-10.1%	+47.4%

Key facts CIK 1326732 CUSIP 98401F105 13F (30d) 65 filings 65 filers Visit website Investor relations

XNCR · Xencor Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance